Quantitative Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Quantitative Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,078	Closed	-$908K	–	422
2021 Q3	$908K	Buy	+10,078	New	+$911K	0.08%	214
2018 Q3	–	Sell	-4,900	Closed	-$376K	–	833
2018 Q2	$376K	Buy	+4,900	New	+$316K	0.01%	641
2017 Q2	–	Sell	-83,700	Closed	-$5.67M	–	857
2017 Q1	$5.67M	Buy	83,700 +64,100	+327%	+$4.89M	0.09%	304
2016 Q4	$1.38M	Buy	+19,600	New	+$1.39M	0.03%	553

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quantitative Investment Management's RARE Position: Q4 2021 in Review

Quantitative Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 10,078 shares — an estimated $908K sold.

Quantitative Investment Management first reported a position in RARE in Q4 2016 and held it in 4 quarters. The position peaked at $5.67M in Q1 2017. 234 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

Quantitative Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
Quantitative Investment Management sold 10,078 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $908K.
Quantitative Investment Management first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 4 quarters.
Quantitative Investment Management's Ultragenyx Pharmaceutical position peaked at $5.67M in Q1 2017.
234 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on Quantitative Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.